Summary: Second-generation drug-eluting stents have shown better results than their predecessors. In this study we compare two second-generation drug stents in patients with unprotected left coronary trunk injuries. Methods and results: 650 patients with unprotected trunk injury were randomized to either XIENCE V (everolimus eluting) or RESOLUTE (zotarolimus eluting) stents. The primary endpoint was the…
ETAP: Endovascular treatment of atherosclerotic popliteal artery lesions: a prospective, multi-center, randomized study.
Introduction: The popliteal artery is a vessel considered unfavorable for the implantation of a stent due to the forces exerted in the popliteal fossa during limb flexion, which could fracture the stent antlers and compromise the outcome of the procedure at long-term. So far, stents used in popliteal lesions have not been compared with balloon…
PARTNER cohort B: Clinical events at 3 years follow-up in patients with
Background: Percutaneous aortic valve implantation (TAVI) is the treatment of choice for patients with severe aortic stenosis considered inoperable according to clinical outcomes at 12 months as reported in the PARTNER study, which demonstrated a reduction in mortality and an improvement in the quality of life for patients. However, the long term benefit of this…
MASTER Trial: Prospective, multicentre, randomized trial evaluating the MGuard stent in the treatment of patients with acute myocardial infarction with ST segment elevation (STEMI).
Foreword: The EPS MGUARD stent (embolic protection stent) has a fine metal structure covered by a thin polyethylene fiber mesh with pores of 5 microns wrapping the stent that might prevent distal embolization during primary angioplasty and would therefore be particularly attractive during primary angioplasty. Methods and Results: We included 432 patients referred for primary…
FAME 2: Cost-effectiveness of FFR-guided angioplasty in patients with stable angina
Introduction: FAME study 2, presented at the European Congress of Cardiology 2012, is a multicenter study that randomized patients with stable angina FFR-guided angioplasty and optimal medical therapy versus optimal medical therapy alone. The study was stopped early due to a significantly higher rate of primary endpoints, (death, MI, or urgent revascularization), in the conservative…
TRILOGY ACS. Prasugrel versus clopidogrel in patients with acute coronary syndromes with non – ST segment elevation treated clinically after angiographic evaluation
Insides : 40%-60% of patients with acute coronary syndrome with non ST elevation (ACS) are treated clinically. Prasugrel proved superior to clopidogrel in patients with ACS undergoing invasive treatment (TRITON-TIMI 38). The TRILOGY ACS randomized multicenter trial assessed prasugrel and clopidogrel in patients with ACS treated clinically. Study results were neutral and have already been…